Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | BCL2A1 | Q16548 | 3/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | AHCY | P23526 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20137099 | 0.88 | LMNA (0.41) | NR1D1BCL2A1ACLYNR1H3SMN1; SMN2 | |
| SCHEMBL20137405 | 0.87 | BCL2A1 (0.38) | NR1D1BCL2A1ACLYBCHEALDH1A1 | |
| SCHEMBL28880216 | 0.78 | BCL2A1 (0.41) | BCL2A1HSP90AA1 | |
| SCHEMBL20150068 | 0.77 | TSPO (0.39) | NR1D1BCHEALDH1A1HTT | |
| SCHEMBL20137411 | 0.74 | LTB4R2 (0.40) | NR1D1NR1H3BCHE | |
| SCHEMBL20151855 | 0.74 | MGLL (0.54) | — | |
| SCHEMBL20137127 | 0.73 | BMP1 (0.37) | NR1D1 | |
| SCHEMBL28699408 | 0.70 | LMNA (0.44) | HRH1HRH4SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL20151851 | 0.67 | PPARD (0.33) | NR1D1 | |
| SCHEMBL20151838 | 0.67 | PPARG (0.39) | BCHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134674-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | NR1D1 2645/4885SIGMAR1 666/4885BCL2A1 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.